IP Library Granted Patent US 8,062,897
Granted Patent B2
US 8,062,897 · App. 11/404,272 · Granted Nov 22, 2011

Diagnostic histopathology using multiplex gene expression FISH

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,062,897
App. No.
11/404,272
Granted
Nov 22, 2011
Kind
B2
Abstract

The present invention relates to a method for detecting one or more nascent RNAs in a tissue sample using FISH. In the method, a plurality of probes (8 to 82) may be used to detect a single species of nascent RNA. Further, a plurality of nascent RNA species may be detected simultaneously using between 8 and 82 probes for each nascent RNA. The invention comprises, in addition, methods of preparing a sample for nascent RNA detection by reducing autofluorescence of the tissue sample. These techniques may be synergistically combined to achieve significantly improved results.

Claims (27)

1. A method for the in situ detection of one or more nascent RNA species in a human paraffin embedded tissue sample comprising the steps of:

a) performing autofluorescence reduction on the human paraffin embedded tissue sample by pressure cooking the tissue sample at a temperature of about 125° C., at a pressure of between 20 to 24 PSI and for a period of 10 minutes to 1 hour to produce a pressure cooked sample, and then treating said pressure cooked sample with ammonia-ethanol at a concentration of 0.1% to 0.5% for between 10 and 50 minutes and sodium borohydride at a concentration of 1% to 5% for between 10 and 50 minutes in any order;

b) hybridizing at least one labeled nucleic acid probe specific for one or more nascent RNA species to the tissue sample;

c) detecting the at least one labeled nucleic acid probe in the tissue sample thereby detecting the presence of the one or more nascent RNA species.

2. The method of claim 1 wherein the tissue sample is from a neoplastic or preneoplastic tissue.

3. The method of claim 1 wherein the ammonia-ethanol is in a concentration of 0.25%.

4. The method of claim 1 wherein treating the pressure cooked sample with ammonia-ethanol comprises contacting the pressure cooked sample with ammonia-ethanol for 10 to 30 minutes.

5. The method of claim 1 wherein treating the pressure cooked sample with ammonia-ethanol comprises contacting the pressure cooked sample with ammonia-ethanol for 40 minutes.

6. The method of claim 1 wherein treating the sample with sodium borohydride comprises contacting the pressure cooked sample with sodium borohydride for 20 minutes.

7. The method of claim 1 wherein the at least one labeled nucleic acid probe is attached to at least one fluorescent moiety.

8. The method of claim 7 wherein the fluorescent moiety is selected from the group consisting of FITC, Cy3, Cy3.5, Cy5, Cy5.5 and DAPI.

9. The method of claim 7 wherein each of said nascent RNA species hybridizes to a plurality of probes with a unique combination of fluorescent moieties for each of said nascent RNA species.

10. The method of claim 7 wherein each of said nascent RNA species hybridizes to 8 or more probes.

11. The method of claim 7 wherein each of said nascent RNA species hybridizes to 12 or more probes.

12. The method of claim 1 wherein the labeled nucleic acid probe comprises a nucleotide sequence of an intron, a 5′ untranslated region or a 3′ untranslated region of a nascent RNA.

13. The method of claim 1 wherein the labeled nucleic acid probe is specific for a 5′ region of the nascent RNA species.

14. The method of claim 1 wherein the labeled nucleic acid probe is specific for a 3′ region of the nascent RNA species.

15. The method of claim 1 further comprising a step of staining the sample after the detecting step.

16. The method of claim 1 wherein the detecting step comprises the step of detecting the labeled nucleic acid probe in the nucleus of a cell in the tissue sample.

17. The method of claim 1 wherein the detecting step detects the labeled nucleic acid probe within 50 micron of its location.

18. The method of claim 1 further comprising the step of determining the location of a chromosome in said tissue sample.

19. The method of claim 1 which is performed in the absence of any added protease.

20. The method of claim 18 wherein determining the location of a chromosome comprises the steps of

(1) hybridizing at least one labeled chromosome specific probe to said tissue sample;

(2) detecting said at least one labeled chromosome specific probe in at least one cell in said tissue sample.

21. The method of claim 20 wherein the step of detecting the labeled chromosome specific probe detects the labeled chromosome specific probe within 50 micron of its location.

22. The method of claim 18 wherein said step of determining the location of a chromosome is performed after step a), after step b), or after step c).

Assignments (7)
THIS IS TO CORRECT ERRORS IN A COVER SHEET PREVIOUSLY RECORDED (REEL/FRAME 027502/0828): CORRECTION OF THE ASSIGNOR'S NAME TO AUREON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC.; CORRECTION OF THE ASSIGNEE'S NAME TO AUREON, INC. Recorded May 22, 2012
From: AUREON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: AUREON, INC.
Reel/Frame 028252/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2012
From: AUREON, INC.
To: CHAMPALIMAUD FOUNDATION
Reel/Frame 028244/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2012
From: AUREON BIOSCIENCES, INC.
To: DAVID SANS
Reel/Frame 027502/0828 →
SECURITY AGREEMENT Recorded Oct 25, 2010
From: AUREON BIOSCIENCES, INC.
To: ATLAS VENTURE FUND VI GMBH & CO. KG; ATLAS VENTURE FUND VI, L.P.; ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.; PFIZER INC.; MINTZ LEVIN INVESTMENTS LLC; SPROUT CAPITAL IX, L.P.; DLJ CAPITAL CORP.; SPROUT ENTREPRENEURS FUND, L.P.; SPROUT IX PLAN INVESTORS, L.P.; CANTABRIA DE ACTIVOS, S.L.; CORPORACION MASAVEU, S.A.; INICIATIVAS DIGITALES; IPETEX S.A.; INVERSIONES VECU 2006, S.L.; LEALTAD DESARROLLO, S.C.R., S.A.; BASSETTI, MARCO; C+PA-CIMENTO E PRODUTOS ASSOCIADOS, S.A.
Reel/Frame 025178/0899 →
SECURITY AGREEMENT Recorded Aug 9, 2010
From: AUREON BIOSCIENCES, INC.
To: ATLAS VENTURE FUND VI, L.P.; ATLAS VENTURE FUND VI GMBH & CO. KG; ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.; SPROUT ENTREPRENEURS FUND, L.P.; SPROUT CAPITAL IX, L.P.; DLJ CAPITAL CORP.; SPROUT IX PLAN INVESTORS, L.P.; PFIZER INC; MINTZ LEVIN INVESTMENTS LLC; INICIATIVAS DIGITALES; INVERSIONES VECU 2006, S.L.; LEALTAD DESARROLLO, S.C.R., S.A.; IPETEX S.A.; CANTABRIA DE ACTIVOS, S.L.; CORPORACION MASAVEU, S.A.; PEREZ DE ARMINAN, ALFREDO; FERNANDEZ DE VILLAVICENCIO, GABRIEL STAMOGLOU; FERNANDEZ DE VILLAVICENCIO, ALEJANDRO STAMOGLOU
Reel/Frame 024946/0493 →
SECURITY AGREEMENT Recorded Jan 12, 2010
From: AUREON LABORATORIES, INC.
To: ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.; ATLAS VENTURE FUND VI GMBH & CO. KG; ATLAS VENTURE FUND VI, L.P.; SPROUT CAPITAL IX, L.P.; DLJ CAPITAL CORP.; SPROUT IX PLAN INVESTORS, L.P.; SPROUT ENTREPRENEURS' FUND, L.P.; PFIZER INC.; CANTABRIA DE ACTIVOS, S.L.; CORPORACION MASAVEU, S.A.; LEALTAD DESARROLLO, S.C.R., S.A.; INICIATIVAS DIGITALES; INVERSIONES VECU 2006, S.L.; MARCO BASSETTI; ESTRELA - SGPS, S.A.; MINTZ LEVIN INVESTMENTS LLC
Reel/Frame 023768/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2006
From: CAPODIECI, PAOLA; DONOVAN, MICHAEL J.
To: AUREON LABORATORIES, INC.
Reel/Frame 017883/0030 →